Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
United StatesIPO:
14 May 2021Website:
http://www.organon.comNext earnings report:
08 August 2024Last dividends:
10 May 2024Next dividends:
N/APrice
after hours | Mon, 01 Jul 2024 23:40:25 GMTAnalysts recommendations
Institutional Ownership
OGN Latest News
In the most recent trading session, Organon (OGN) closed at $20.63, indicating a -0.77% shift from the previous trading day.
Organon (OGN) closed the most recent trading day at $20.45, moving +0.49% from the previous trading session.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Organon (OGN) stock has begun to rise and could continue to increase in the near future, supported by strong adjustments to earnings forecasts.
There is a possibility that Organon (OGN) could increase in value due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).
Organon (OGN) reported quarterly earnings of $1.22 per share, surpassing the Zacks Consensus Estimate of $0.97 per share. This is higher than the earnings of $1.08 per share from the previous year.
Organon's (OGN) first-quarter earnings are expected to show an increase in biosimilars and established brand franchises, offset by lower fertility product sales due to currency fluctuations.
Instead of focusing solely on Wall Street's predictions for Organon (OGN) in terms of revenue and earnings, it is important to analyze other important metrics to better understand the company's potential performance in the first quarter of 2024.
Organon (OGN) lacks the necessary elements for a potential earnings surpass in its upcoming report. Be ready with the important projections.
Organon (OGN) ended the most recent trading day at $18.71, showing a 1.03% increase from its previous closing price.
- 1(current)
- 2
What type of business is Organon & Co?
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.
What sector is Organon & Co in?
Organon & Co is in the Healthcare sector
What industry is Organon & Co in?
Organon & Co is in the Drug Manufacturers - General industry
What country is Organon & Co from?
Organon & Co is headquartered in United States
When did Organon & Co go public?
Organon & Co initial public offering (IPO) was on 14 May 2021
What is Organon & Co website?
https://www.organon.com
Is Organon & Co in the S&P 500?
No, Organon & Co is not included in the S&P 500 index
Is Organon & Co in the NASDAQ 100?
No, Organon & Co is not included in the NASDAQ 100 index
Is Organon & Co in the Dow Jones?
No, Organon & Co is not included in the Dow Jones index
When does Organon & Co report earnings?
The next expected earnings date for Organon & Co is 08 August 2024